Study of 11,441 Mindbloom Clients Shows Effectiveness and Safety of At-Home Ketamine Therapy

Mindbloom, a prominent provider of psychedelic therapy based in Austin, Texas, has released groundbreaking findings from the most extensive peer-reviewed study on ketamine therapy and psychedelic medicine. Published in the Journal of Affective Disorders, the research was conducted by experts from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom. This study sheds light on the effectiveness and safety of at-home, telehealth-supported ketamine treatment for depression and anxiety.

The study analyzed data from 11,441 Mindbloom clients, making it the largest examination of ketamine therapy ever conducted. The results were promising: 62% of clients reported significant improvements in depression or anxiety symptoms, with 28% achieving complete remission. Notably, these improvements were often observed after only four treatment sessions, showcasing the rapid efficacy of ketamine therapy.

Safety was another crucial aspect of the study. Less than 5% of clients experienced adverse effects, underscoring the treatment's safety profile. Another important finding was the benefits of sustained treatment. Among clients who experienced significant improvements initially, 84% either maintained those improvements or recovered further during a second round of treatment.

Dr. Leonardo Vando, Mindbloom's Medical Director and co-author of the study, emphasized the significance of these findings. "Millions of Americans struggle with mental illness and find little relief from traditional treatments. This study demonstrates that at-home ketamine therapy can be a fast-acting and effective alternative for treating depression and anxiety. It also highlights the potential for psychedelic therapy to become a leading treatment option in the near future," Vando noted.

The study also highlighted the comprehensive support system provided by Mindbloom, which includes one-on-one coaching, therapeutic content, and group integration. This extensive support plays a crucial role in ensuring the effectiveness and safety of the treatment. Furthermore, Mindbloom's at-home therapy model helps overcome barriers such as cost, provider availability, and stigma, making mental health care more accessible to a broader population.

Dylan Beynon, Founder and CEO of Mindbloom, reiterated the success of the at-home telehealth model. "Our programs are effective because of, not despite, our at-home model. Telehealth makes treatment more accessible and affordable, allowing clients to undergo therapy from the comfort of their own homes. Since our inception in 2019, there have been doubts about the safety and effectiveness of delivering ketamine therapy via telehealth. This study decisively answers those doubts," Beynon stated.

This research is the second peer-reviewed study of Mindbloom's clinical outcomes, supporting the findings of the first study with a much larger sample size. The new study also incorporates advanced analysis, using artificial intelligence and machine learning tools to predict client responses to treatment. This predictive capability provides clinicians with valuable insights, enabling them to better support their clients.

Mindbloom stands as the largest provider of psychedelic medicine, facilitating over 275,000 at-home ketamine therapy sessions annually across 36 states. The company offers comprehensive programs that combine evidence-based medicine with coaching, content, and community support, addressing a range of mental health issues.

These findings mark a significant step forward in the field of psychedelic medicine, providing robust evidence for the efficacy and safety of at-home ketamine therapy. As the mental health crisis continues to grow, innovative treatments like those offered by Mindbloom could play a crucial role in providing relief to millions of individuals.